Fighting virus with Donor's own defenses after transplant
NCT ID NCT07476014
Summary
This early-stage study tests whether special immune cells from a stem cell donor can prevent Epstein-Barr virus (EBV) infection in transplant patients. Researchers will give these donor-derived cells to 9-18 patients who are at high risk for EBV infection after their transplant. The main goal is to check if this treatment is safe and if it reduces EBV infections in these vulnerable patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF EBV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.